Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | WNT3A | P56704 | 1/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23019453 | 0.86 | MET (0.52) | ROCK2ROCK1DGAT1MAPK1AURKB | |
| SCHEMBL21426361 | 0.84 | AURKB (0.74) | MAPK1AURKB | |
| SCHEMBL14507349 | 0.82 | SMN1; SMN2 (0.62) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL31241108 | 0.82 | RAB9A (0.60) | MAPK1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL1269593 | 0.82 | RAB9A (0.60) | MAPK1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL21286264 | 0.81 | WNT3A (0.78) | WNT3AMEN1KMT2A | |
| SCHEMBL14302228 | 0.80 | NAMPT (0.62) | ROCK2ROCK1AURKBALDH1A1LMNA | |
| SCHEMBL10133206 | 0.80 | ROCK2 (0.80) | ROCK2ROCK1RORCMEN1KMT2A | |
| SCHEMBL4876684 | 0.79 | DEGS1 (0.58) | DGAT1WNT3AMEN1KMT2A | |
| SCHEMBL10133030 | 0.79 | TUBB4A (0.58) | MAPK1AURKBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | ROCK2 377/4885ROCK1 432/4885DGAT1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.